Document text
Principal Investigator: Judith S. Currier
Organization: UNIVERSITY OF CALIFORNIA LOS ANGELES
Fiscal Year: 2021
Award: $19,807,516
Funding agency: National Institute of Allergy and Infectious Diseases
Abstract
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the
Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2 (CoVPN 3502)
Transmission of SARS-CoV-2 occurs primarily through person-to-person contact and respiratory
droplet transmission (Lai,2020). Household contacts of a person infected with SARS-CoV-2 are
at a high risk for acquiring infection, with transmission rates ranging from approximately 10% to
15%. The majority of individuals who acquire infection from household contacts develop
symptoms of COVID-19 (Burke,2020) (Jing, 2020), (Bi,2020) (Li,2020b). Prophylaxis is urgently
needed to reduce transmission rates and/or reduce the occurrence of symptomatic disease.
Ideally, prophylaxis would need to be given as soon as possible after a known exposure, as the
duration of time between symptomatic infection in the source individual and the development of symptoms in newly infected individual is thought to be approximately 5 days, with a possible range of 2 to14 days(Lauer,2020) (Li,2020a). Animal models suggest that SARS-CoV-2 RT-PCR in nasopharyngeal (NP) samples become positive within a few days after infection (Rockx,2020). An ideal agent for prophylaxis should be fast acting and highly effective and should protect against multiple viral variants. A monoclonal antibody (mAb) combination therapy, with two different monoclonal antibodies that bind distinct regions of the portion of the SARS-CoV-2 spike(S) protein that bind to and facilitate entry into host cells, has been developed in order to achieve these goals.
A mAb combination against SARS-CoV-2 for post-exposure prophylaxis that can either prevent the development of disease or reduce viral acquisition or shedding could be key to reducing transmission of the virus and limiting symptoms and adverse outcomes following infection.
Given the speed at which this outbreak has spread and how it has impacted almost every
community globally, there is an urgent need to develop safe and efficacious interventions to slow the spread of the SARS-CoV-2 virus and decrease adverse outcomes associated with
symptomatic disease.
This study is designed to assess the efficacy and safety of co-administered REGN10933+REGN10987 combination therapy (“REGN10933+REGN10987”) to reduce the
proportion of SARS-CoV-2 infections and prevent the development of COVID-19 disease
(symptomatic SARS-CoV2 infection), after household exposure to individuals with SARS-CoV-2
infection.
ACTIV-2/A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) – Brii Biosciences Agent
Adapt Out COVID is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19. It begins with a phase II evaluation, followed by a transition into a larger phase III evaluation for promising agents. This supplement represents activity for the Brii Biosciences Agent.
The trial is a randomized, blinded, controlled adaptive platform that allows agents to be added and dropped during the course of the study for efficient testing of new agents against placebo within the same trial infrastructure. When two or more new agents are being tested concurrently, the same placebo will be used, if feasible.
The primary outcome measures in the phase II evaluation will be duration of symptoms, similar to the outcome used for outpatient influenza studies, loss of detection of SARS-CoV-2 RNA by nasopharyngeal (NP) swab, and safety. Determination of whether a phase II agent will continue to be evaluated in phase III will be made after the last participant randomized to that agent or placebo group completes their day 28 phase II visit. If continued, data collected from participants enrolled in phase II will be included in the phase III evaluation.
The phase III evaluation is a continuation of the phase II trial for agents that meet study-defined criteria for further evaluation and for which sufficient investigational agent is available. An agent may also enter directly into phase III evaluation based on Trial Oversight Committee (TOC) assessments. The fully powered phase III trial will evaluate the efficacy of each selected investigational agent compared to placebo to prevent hospitalization and death in non-hospitalized adults with COVID-19.
The protocol will be amended when information becomes available from within or outside of the trial indicating that further randomization to a placebo is inappropriate.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><21+ years old><Accident and Emergency department><Address><Adult><Adult Human><Age><Animal Model><Animal Models and Related Studies><Binding><Binding Proteins><Biologic Sciences><Biological Sciences><Bioscience><Blinded><COVID><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 Prevention Network><COVID-19 S protein><COVID-19 crisis><COVID-19 detection><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 severity><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 transmission><COVID-19 virus><COVID-19 virus transmission><COVID19><COVID19 detection><COVID19 S protein><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 severity><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><CV-19><CV19><Cell Body><Cells><Cessation of life><Clinical Treatment Moab><CoV disease><CoV-2><CoV2><CoVPN><Combined Modality Therapy><Communities><Data><Death><Development><Disease><Disease Outbreaks><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Drops><Drug Kinetics><Emergency Department><Emergency room><Enrollment><Evaluation><Exposure to><Goals><Grippe><Health Facilities><Health care facility><Healthcare Facility><Hospital Admission><Hospitalization><Hospitals><Hour><Household><Individual><Infection><Influenza><Infrastructure><Institutes><Investigation><Life Sciences><Ligand Binding Protein><Ligand Binding Protein Gene><Measurement><Medical><Molecular Interaction><Monoclonal Antibodies><Multimodal Therapy><Multimodal Treatment><New Agents><Non-Polyadenylated RNA><Out-patients><Outbreaks><Outcome><Outcome Measure><Outpatients><Participant><Persons><Pharmacokinetics><Phase><Placebos><Population><Prophylactic treatment><Prophylaxis><Protein Binding><Protocol><Protocols documentation><Pulse Oximetry><RNA><RNA Gene Products><RT-PCR><RTPCR><Randomized><Reducing Agents><Reductants><Reverse Transcriptase Polymerase Chain Reaction><Ribonucleic Acid><Risk><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 detection><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 severity><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 transmission><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Saliva><Sampling><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Severities><Sham Treatment><Source><Speed><Subgroup><Symptoms><Testing><Time><Transmission><Variant><Variation><Viral><Virus><Visit><Wuhan coronavirus><acute care><adulthood><adverse consequence><adverse outcome><ages><associated symptom><base><bound protein><care facilities><co-morbid><co-morbid symptom><co-morbidity><co-occuring symptom><cohort><combination therapy><combined modality treatment><combined treatment><comorbid symptom><comorbidity><concurrent symptom><cooccuring symptom><corona virus disease><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 detection><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention network><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 transmission><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><design><designing><detect COVID-19><detect COVID19><detect SARS-CoV-2><detect severe acute respiratory syndrome coronavirus 2><developmental><efficacious intervention><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy study><enroll><evaluate efficacy><examine efficacy><hCoV19><high risk><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mAbs><model of animal><model organism><multi-modal therapy><multi-modal treatment><nCoV2><nasal swab><nasopharyngeal swab><phase 2 evaluation><phase 2 testing><phase 2 trial><phase 3 evaluation><phase 3 testing><phase 3 trial><phase II evaluation><phase II testing><phase II trial><phase III evaluation><phase III testing><phase III trial><placebo controlled study><placebo group><prevent><preventing><primary outcome><public health relevance><randomisation><randomization><randomly assigned><respiratory><reverse transcriptase PCR><screen time><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 detection><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 transmission><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sham group><sham therapy><subcutaneous><subdermal><symptom association><symptom comorbidity><symptom treatment><symptomatic treatment><television watching><transmission process><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2><treat symptom><treatment group><treatment trial><tv watching><viral transmission><virus transmission>